Table 1.
Description of the Sample (N=534)
| N (column %) | Received a GEP Test N (row %) |
p-value for comparison between categories |
|
|---|---|---|---|
| Received a GEP test | |||
| Yes | 138 (25.8) | ||
| No | 396 (74.2) | ||
| Age at diagnosis: | P=0.11 | ||
| 30 – 49 years | 209 (39.1) | 46 (22.0) | |
| 50 – 64 years | 325 (61.9) | 92 (28.3) | |
| Comorbidity score: | |||
| 0 | 447 (83.7) | 125 (28.0) | P=0.01 |
| ≥ 1 | 87 (16.3) | 13 (14.9) | |
| Breast cancer stage | |||
| I | 241 (45.1) | 101 (41.9) | P<0.001 |
| II | 234 (43.8) | 37 (15.8) | |
| III | 59 (11.1) | 0 (0.0) | |
| Tumor size | |||
| ≤ 1cm | 106 (20.8) | 24 (22.6) | P<0.001 |
| 1.01cm – 2cm | 227 (44.5) | 82 (36.1) | |
| 2.01cm – 3cm | 115 (22.5) | 26 (22.6) | |
| > 3cm | 62 (12.2) | 4 (6.5) | |
| Axillary lymph node involvement | |||
| None | 315 (59.5) | 130 (41.3) | P<0.001 |
| Any | 214 (40.5) | 8 (3.7) | |
| Summary Grade | |||
| Well-differentiated | 127 (25.0) | 46 (36.2) | P=0.001 |
| Moderately-differentiated | 236 (46.5) | 65 (27.5) | |
| Poorly-differentiated | 145 (28.5) | 24 (16.6) | |
| Hormone receptor status | |||
| Either ER or PR positive | 75 (14.0) | 19 (25.3) | P=0.91 |
| Both ER and PR positive | 459 (86.0) | 119 (25.9) | |
| HER2 status | |||
| Negative or intermediate | 445 (84.1) | 124 (27.8) | P=0.03 |
| Positive | 84 (15.9) | 14 (16.7) | |
| Clinical risk of recurrence | |||
| Low | 60 (11.2) | 15 (25.0) | P<0.001 |
| Moderate | 204 (38.2) | 106 (52.0) | |
| High | 253 (47.4) | 14 (5.5) | |
| Unknown | 17 (3.2) | 3 (17.7) | |
| Year of diagnosis | |||
| 2006 | 214 (40.1) | 42 (19.6) | P<0.001 |
| 2007 | 252 (47.2) | 68 (27.0) | |
| 2008 | 68 (12.7) | 28 (41.2) | |
Notes: Percentages calculated based on those with valid data. Data were missing for tumor size (n=24), nodal involvement (n=5), tumor grade (n=26), and HER2 status (n=5).
ER: Estrogen receptor
PR: Progesterone receptor
HER2: human epidermal growth factor receptor.